Innovation Insights: Targeted Delivery of Oligos to Kidney/Heart

Targeted Delivery of Oligonucleotides explores the innovative strategies and technologies used to deliver oligonucleotides to specific cells or tissues in the body. Oligonucleotides are short DNA or RNA molecules that have the potential to treat a wide range of diseases, but their effectiveness is often limited by the challenges of delivering them to the right location in the body.
The book covers various approaches to targeted delivery, including the use of nanoparticles, liposomes, and other delivery vehicles to encapsulate and protect oligonucleotides until they reach their intended target. It also discusses the importance of targeting specific cell types or tissues to maximize the therapeutic effects of oligonucleotide-based treatments.
With contributions from leading experts in the field, "Targeted Delivery of Oligonucleotides" provides a comprehensive overview of the current state of the art in oligonucleotide delivery and offers insights into future directions for research and development in this exciting and rapidly evolving field.

Targeted delivery of oligonucleotides is a significant innovation in the mid-term for the medical field. Research and development in this area is mainly conducted by universities, but commercial players are starting to become more involved in creating new innovations. Although there is less citation activity due to the specialized nature of this innovation, patent filings are increasing, with universities, big pharma, and small biotech companies leading the way. The United States is the primary location for these patents, with a focus on rare diseases in cardiovascular and renal disease categories.
Novo Nordisk is a key player in patent filings, especially after acquiring Dicerna Pharmaceuticals. There are over 150 companies involved in this space, with a growing presence in China. Startups like Silence Therapeutics, Feldan Biotech, and Cella Therapeutics are making strides in developing targeted delivery of oligonucleotides for kidney and heart diseases.
The drug landscape for targeted delivery of oligonucleotides to kidney and heart diseases includes 32 drugs, primarily focused on cardiology and metabolic disorders. Subcutaneous administration is the most common route for these drugs, with companies like Sirnamoics Ltd and Ionis Pharma leading in drug development and clinical trials. Novartis AG and Ionis Pharmaceuticals are sponsoring the most clinical trials, with a focus on metabolic disorders and hypercholesterolemia.
In terms of deals, there have been 58 totaling $53.2 billion, with the United States leading in deal volume and value. The market saw a peak in 2023, followed by a slight decrease in 2024, indicating potential market adjustments and strategic consolidations.

How is our ‘State of Innovation intelligence 2024’ report unique from other reports in the market?

Precision-Targeted Approach - Unlike general oligonucleotides reports, this report focuses exclusively on oligonucleotide delivery strategies for the kidney and heart, addressing key leaders, startups, university, their patenting activity, and respective deals.
Drugs & Clinical Landscape - Stay updated on organ-specific regulatory challenges, Drug molecule type, and clinical trial advancements, critical for optimizing delivery strategies.
Competitive & Market Intelligence - Gain insights into leading pharmaceutical companies, biotech startups, and academic institutions pioneering kidney and heart-specific oligo therapies.
Investment & Partnership Opportunities - Identify funding trends, licensing deals, and collaboration opportunities, helping businesses align their strategies with the evolving market landscape.

We recommend this valuable source of information to anyone involved in:

​​​​Drug Development and ​​​​Pharma/Biotech Companies - Value chain

Pharmaceutical Industry Suppliers and Distributors

Pharma/Drug Manufacturing Companies - Leaders and Startups

Business Development and Market Intelligence

Investment Analysts and Portfolio Managers

Professional Services - Investment Banks, PE/VC Firms

M&A/Investment, Management Consultants, and Consulting Firms

Key Highlights

• Targeted delivery of oligonucleotides report is a high-impact innovation area in the Pharma industry, with a growing number of patents being filed and a focus on new indications such as Cardiac Diseases.
• Big pharma companies like Novo Nordisk dominate the patent activity in Targeted delivery of oligonucleotides with a dip in new companies filing patents in recent years.
• Competitive intelligence shows that Alnylam in terms of portfolio size are among the leaders with strong innovation portfolios in Targeted delivery of oligonucleotides.
• The drug landscape for Targeted delivery of oligonucleotides is dominated by innovator drugs, with a focus on Cardiovascular and Metabolic disorders, and major players like Sirnaomics and Ionis leading in drug development.
• Clinical trials in Targeted delivery of oligonucleotides are dominated by Metabolic Disorders trials, with the Novartis AG and Ionis Pharma leading in the number of trials.

Scope

• Innovation Insights: innovation examples by each use cases segment of various sectors to present key trends.
• Key player: This represents a sample list of key players in each use case highlighted in the report.
• Startups: This represents a sample list of emerging starups in each use case highlighted in the report.
• University: This represents a sample list of leading universities in each use case highlighted in the report.

Reasons to Buy

• Stay Ahead in a High-Potential Market - The targeted delivery of oligonucleotides to the kidney and heart is an evolving area with huge therapeutic potential. This report helps you stay ahead of competitors by providing cutting-edge insights.
• Comprehensive Scientific & Market Intelligence - Gain detailed analysis of the latest delivery technologies, preclinical & clinical developments, and emerging innovations in oligonucleotide-based therapies.
• Identify Investment & Partnership Opportunities - The report highlights funding trends, licensing deals, and strategic collaborations, allowing investors and pharma leaders to make informed business decisions.
• Understand Regulatory & Clinical Challenges - Navigate the complex regulatory landscape for organ-specific oligo delivery, ensuring compliance and risk mitigation in drug development.
• Competitive Benchmarking - Track the activities of leading pharma companies, biotech startups, and academic institutions, helping you benchmark strategies and identify potential collaborators.
• Strategic R&D Planning - Leverage insights into emerging delivery platforms, mechanisms of action, and target validation to refine your research and development approach.